Active substance
Ampicillin
- SFDA 7
- US FDA 36
- Health Canada 17
- US price lines 1
- NHS prices 1
- WHO EML 2
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| EPICOCILLIN VIAL 1G | 1 g | powder for solution for injection · Intravenous use | 1 Vial | SAR 9.05 | Generic · Prescription | EIPICO | Valid |
| EPICOCILLIN VIAL 500MG | 500 mg | powder for solution for injection · Intravenous use | 1 Vial | SAR 6.45 | Generic · Prescription | EIPICO | Valid |
| STANDACILLIN 1G VIAL WITH SOLVENT | 1 g | Powder and solvent for solution for injection/infusion · Intravenous use | 1 Vial | SAR 14.65 | Generic · Prescription | SANDOZ | Valid |
| STANDACILLIN 500MG INJ WITH SOLVENT | 500 mg | Powder and solvent for solution for injection/infusion · Intravenous use | 1 Vial | SAR 7.75 | Generic · Prescription | SANDOZ | Valid |
| AMPICILLIN 1GM POWDER FOR IV AND IM INJECTION | 1 g | powder for solution for injection · Intramuscular and intravenous use | 50 Vial | SAR 198.85 | Generic · Prescription | ANTIBIOTIC S.E | Withdrawn by MAH · Not Marketed |
| AMPICILLIN 500MG POWDER FOR IV AND IM INJECTION | 500 mg | powder for solution for injection · Intramuscular and intravenous use | 50 Vial | SAR 147.40 | Generic · Prescription | ANTIBIOTIC S.E | Withdrawn by MAH · Not Marketed |
| PENBRITIN VIAL 250 MG | 250 mg | Solution · Intravenous use | 10 Vial | SAR 35.65 | NCE · Prescription | SMIITHKLINE BEECHAM | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE PANCREATITIS; ACUTE PYELONEPHRITIS; BACTERIAL MENINGITIS; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT - SHIGELLA INFECTIONS; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT - TYPHOID AND PARATYPHOID FEVERS; COMMUNITY ACQUIRED PNEUMONEA; ENDOCARDITIS; INTRA-ABDOMINAL INFECTIONS; MATERNAL AND CHILD HEALTHCARE- PROPHYLAXIS FOR P-PROM, DELIVERY BY C-SECTION, GROUP B STREPTOCOCCUS; OSTEOMYELITIS; PERITONITIS; PREVENTION AND CHEMOPROPHYLAXIS OF BACTERIAL MENINGITIS- STREPTOCOCCUS B CARRIER STATE COMPLICATING PREGNANCY, CHILDBIRTH AND THE PUERPERIUM; Pyogenic Arthritis; RECURRENT URINARY TRACT INFECTIONS (UTI); TRAVEL RELATED INFECTIONS-TREATMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| AMPICILLIN SODIUM | EQ 125MG BASE/VIAL; EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL; EQ 10GM BASE/VIAL | injectable · injection | SANDOZ | Prescription | 3 Mar 1971 |
| AMPICILLIN SODIUM | EQ 250MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL | injectable · injection | ACS DOBFAR SPA | Prescription | 12 May 1987 |
| AMPICILLIN SODIUM | EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL | injectable · injection | HQ SPECLT PHARMA | Prescription | 15 Apr 1993 |
| AMPICILLIN SODIUM | EQ 10GM BASE/VIAL | injectable · injection | HQ SPECLT PHARMA | Prescription | 15 Apr 1993 |
| AMPICILLIN SODIUM | EQ 2GM BASE/VIAL | injectable · injection | ACS DOBFAR SPA | Prescription | 12 Jul 1993 |
| AMPICILLIN SODIUM | EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | ANTIBIOTICE | Prescription | 28 Dec 2009 |
| AMPICILLIN SODIUM | EQ 10GM BASE/VIAL | injectable · injection | EUGIA PHARMA SPECLTS | Prescription | 17 Aug 2010 |
| AMPICILLIN SODIUM | EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | EUGIA PHARMA SPECLTS | Prescription | 17 Aug 2010 |
| AMPICILLIN SODIUM | EQ 10GM BASE/VIAL | injectable · injection | ACS DOBFAR SPA | Prescription | 3 Apr 2013 |
| AMPICILLIN SODIUM | EQ 10GM BASE/VIAL | injectable · injection | ACS DOBFAR SPA | Prescription | 20 Dec 2013 |
| AMPICILLIN SODIUM | EQ 10GM BASE/VIAL | injectable · injection | ONESOURCE SPECIALTY | Prescription | 7 Apr 2014 |
| AMPICILLIN SODIUM | EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | ONESOURCE SPECIALTY | Prescription | 9 Apr 2014 |
| AMPICILLIN SODIUM | EQ 10GM BASE/VIAL | injectable · injection | SAGENT PHARMS INC | Prescription | 20 Oct 2015 |
| AMPICILLIN SODIUM | EQ 125MG BASE/VIAL; EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | SAGENT PHARMS INC | Prescription | 27 Nov 2015 |
| PENBRITIN-S | EQ 125MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 4GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | WYETH AYERST | Discontinued | 29 Dec 1966 |
| AMPICILLIN SODIUM | EQ 125MG BASE/VIAL; EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL; EQ 10GM BASE/VIAL | injectable · injection | HIKMA | Discontinued | 24 Jun 1986 |
| TOTACILLIN-N | EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | GLAXOSMITHKLINE | Discontinued | 19 Dec 1986 |
| AMPICILLIN SODIUM | EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | powder · intravenous | SANDOZ | Discontinued | 19 Feb 1987 |
| AMPICILLIN SODIUM | EQ 10GM BASE/VIAL | injectable · injection | WATSON LABS INC | Discontinued | 15 Sep 1988 |
| AMPICILLIN SODIUM | EQ 125MG BASE/VIAL; EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | WATSON LABS INC | Discontinued | 28 Oct 1988 |
| AMPICILLIN SODIUM | EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL; EQ 125MG BASE/VIAL; EQ 500MG BASE/VIAL | injectable · injection | HQ SPECLT PHARMA | Discontinued | 15 Apr 1993 |
| AMPICILLIN SODIUM | EQ 500MG BASE/VIAL | injectable · injection | HANFORD GC | Discontinued | 15 Apr 1993 |
| AMPICILLIN SODIUM | EQ 125MG BASE/VIAL | injectable · injection | ACS DOBFAR SPA | Discontinued | 12 Jul 1993 |
| AMPICILLIN SODIUM | EQ 125MG BASE/VIAL | injectable · injection | EUGIA PHARMA SPECLTS | Discontinued | 17 Aug 2010 |
| AMPICILLIN SODIUM | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | ACS DOBFAR SPA | Discontinued | 3 Apr 2013 |
11 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AMPICILLIN FOR INJECTION, USP | 02226995 | 2 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| AMPICILLIN FOR INJECTION, USP | 02227002 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| AMPICILLIN FOR INJECTION, USP | 02227010 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| AMPICILLIN FOR INJECTION, USP | 02227029 | 250 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | FRESENIUS KABI CANADA LTD |
| AMPICILLIN SODIUM FOR INJECTION BP | 02462303 | 250 MG / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | AURO PHARMA INC |
| AMPICILLIN SODIUM FOR INJECTION BP | 02462311 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | AURO PHARMA INC |
| AMPICILLIN SODIUM FOR INJECTION BP | 02462338 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | AURO PHARMA INC |
| AMPICILLIN SODIUM FOR INJECTION BP | 02462346 | 2 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | AURO PHARMA INC |
| AMPICILLIN SODIUM FOR INJECTION BP | 02530481 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | EUGIA PHARMA INC. |
| AMPICILLIN SODIUM FOR INJECTION BP | 02530503 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | EUGIA PHARMA INC. |
| AMPICILLIN SODIUM FOR INJECTION BP | 02530511 | 2 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | EUGIA PHARMA INC. |
| AMPICILLIN SODIUM FOR INJECTION, USP | 00872644 | 250 MG / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | TEVA CANADA LIMITED |
| AMPICILLIN SODIUM FOR INJECTION, USP | 00872652 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | TEVA CANADA LIMITED |
| AMPICILLIN SODIUM FOR INJECTION, USP | 01933345 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | TEVA CANADA LIMITED |
| AMPICILLIN SODIUM FOR INJECTION, USP | 01933353 | 2 G / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | TEVA CANADA LIMITED |
| TEVA-AMPICILLIN | 00020877 | 250 MG | CAPSULE · ORAL | TEVA CANADA LIMITED |
| TEVA-AMPICILLIN | 00020885 | 500 MG | CAPSULE · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | AMPICILLIN 500 MG CAPSULE | $0.44112 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Ampicillin 500mg capsules | £47.96 | 28 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.1. Access group antibiotics · core
First choice: Bacterial pneumonia (Community-acquired pneumonia - severe) [children]; First choice: Acute malnutrition in infants, children or adolescents (complicated) [children]; First choice: Sepsis without septic shock (co-prescribed with gentamicin); First choice: Peritoneal abscess (mild-moderate) (co-prescribed with gentamicin); First choice: Peritoneal abscess (severe) (co-prescribed with gentamicin); First choice: Peritonitis (mild-moderate) (co-prescribed with gentamicin); First choice: Peritonitis (severe) (co-prescribed with gentamicin); Second choice: Bacterial meningitis
Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection (EMLc); 1 g in vial (as sodium salt) powder for injection (EMLc) | Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection - 5.1.6.1. Medicines for bacterial central nervous system infections · core
Second choice: Bacterial meningitis
Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Safety signals and safety-related labeling changes
- US FDA 5 Nov 2025 UNASYN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions
Combinations containing Ampicillin
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.